NO20035358D0 - Somatostatin-dopamin chimere analoger - Google Patents

Somatostatin-dopamin chimere analoger

Info

Publication number
NO20035358D0
NO20035358D0 NO20035358A NO20035358A NO20035358D0 NO 20035358 D0 NO20035358 D0 NO 20035358D0 NO 20035358 A NO20035358 A NO 20035358A NO 20035358 A NO20035358 A NO 20035358A NO 20035358 D0 NO20035358 D0 NO 20035358D0
Authority
NO
Norway
Prior art keywords
somatostatin
dopamine chimeric
chimeric analogs
analogs
dopamine
Prior art date
Application number
NO20035358A
Other languages
English (en)
Other versions
NO332042B1 (no
Inventor
Zheng Xin Dong
Sun H Kim
Jacques-Pierre Moreau
Michael Dewitt Culler
Original Assignee
Sod Conseils Rech Applic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic
Publication of NO20035358D0 publication Critical patent/NO20035358D0/no
Publication of NO332042B1 publication Critical patent/NO332042B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/02—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with hydrocarbon or substituted hydrocarbon radicals, attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • C07D457/06—Lysergic acid amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/10—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with hetero atoms directly attached in position 8
    • C07D457/12—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C07K14/6555—Somatostatins at least 1 amino acid in D-form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
NO20035358A 2001-06-08 2003-12-02 Somatostatin-dopamin kimere analoger, farmasoytiske sammensetninger omfattende slike samt anvendelse av slike for fremstilling av medikament for behandling av sykdom. NO332042B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29705901P 2001-06-08 2001-06-08
PCT/US2002/017859 WO2002100888A1 (en) 2001-06-08 2002-06-07 Somatostatin-dopamine chimeric analogs

Publications (2)

Publication Number Publication Date
NO20035358D0 true NO20035358D0 (no) 2003-12-02
NO332042B1 NO332042B1 (no) 2012-06-11

Family

ID=23144680

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20035358A NO332042B1 (no) 2001-06-08 2003-12-02 Somatostatin-dopamin kimere analoger, farmasoytiske sammensetninger omfattende slike samt anvendelse av slike for fremstilling av medikament for behandling av sykdom.
NO20111165A NO338459B1 (no) 2001-06-08 2011-08-26 Somatostatin-dopamin chimere analoger, samt fremgangsmåte for fremstilling av slike.

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20111165A NO338459B1 (no) 2001-06-08 2011-08-26 Somatostatin-dopamin chimere analoger, samt fremgangsmåte for fremstilling av slike.

Country Status (25)

Country Link
US (4) US7579435B2 (no)
EP (2) EP2062914B1 (no)
JP (2) JP3996897B2 (no)
KR (3) KR100620435B1 (no)
CN (2) CN101481405A (no)
AR (1) AR037226A1 (no)
AT (1) ATE424414T1 (no)
AU (1) AU2002305845B2 (no)
BR (1) BR0210915A (no)
CA (1) CA2449634C (no)
CZ (1) CZ305160B6 (no)
DE (1) DE60231403D1 (no)
DK (2) DK1401863T3 (no)
ES (2) ES2325880T3 (no)
HK (1) HK1060360A1 (no)
HU (1) HUP0400245A3 (no)
IL (2) IL158922A0 (no)
MX (1) MXPA03011321A (no)
NO (2) NO332042B1 (no)
NZ (1) NZ530007A (no)
PL (1) PL216217B1 (no)
PT (2) PT1401863E (no)
RU (1) RU2277539C2 (no)
TW (1) TWI318214B (no)
WO (1) WO2002100888A1 (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003028527A2 (en) * 2001-09-21 2003-04-10 The Administrators Of The Tulane Educational Fund Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof
AU2008200694B2 (en) * 2003-04-11 2011-04-14 Ipsen Pharma S.A.S. Method of treating acromegaly, hyperprolactinemia, portal hypertension and gastrointestinal bleeding with somatostatin-dopamine chimeric analogs
RU2329273C2 (ru) * 2003-04-11 2008-07-20 Сосьете Де Консей Де Решерш Э Д`Аппликасьон Сьентифик С.А.С. Химерные аналоги лигандов соматостатиновых и допаминовых рецепторов, фармацевтические композиции на их основе и способы воздействия на рецепторы соматостатина и/или допамина
SG173223A1 (en) * 2003-04-22 2011-08-29 Ipsen Pharma Sas Peptide vectors
DE10325813B4 (de) * 2003-06-06 2007-12-20 Universitätsklinikum Freiburg Prophylaxe und/oder Therapie bei der portalen Hypertonie
JP2008539246A (ja) * 2005-04-28 2008-11-13 フェリング ベスローテン フェンノートシャップ Ｉｂｄ治療のための新規化合物の使用
US9098855B2 (en) * 2006-05-23 2015-08-04 Intelligent Clearing Network, Inc. Intelligent clearing network
RU2464039C2 (ru) * 2008-05-14 2012-10-20 Ипсен Фарма С.А.С. Фармацевтические композиции конъюгатов соматостатин-дофамин
FR2949469A1 (fr) * 2009-08-25 2011-03-04 Sanofi Aventis Derives anticancereux, leur preparation et leur application en therapeutique
WO2011104627A1 (en) * 2010-02-24 2011-09-01 Ipsen Pharma S.A.S. Metabolites of dop2-d-lys(dop2)-cyclo[cys-tyr-d-trp-lys-abu-cys]-thr-nh2
BR112013027150A2 (pt) * 2011-04-21 2017-06-06 Theratechnologies Inc thera
KR101996700B1 (ko) 2011-12-23 2019-07-04 입센 메뉴팩츄링 아일랜드 리미티드 치료 펩티드의 합성 방법
US9620430B2 (en) 2012-01-23 2017-04-11 Taiwan Semiconductor Manufacturing Company, Ltd. Sawing underfill in packaging processes
TWI523863B (zh) * 2012-11-01 2016-03-01 艾普森藥品公司 體抑素－多巴胺嵌合體類似物
JP2016503402A (ja) 2012-11-01 2016-02-04 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエＩｐｓｅｎ Ｐｈａｒｍａ Ｓ．Ａ．Ｓ． ソマトスタチン類似体及びそのダイマー
US9096679B2 (en) 2012-12-03 2015-08-04 The Board Of Regents Of The University Of Oklahoma Peptide compounds and methods of production and use thereof
WO2014089088A1 (en) * 2012-12-03 2014-06-12 The Board Of Regents Of The University Of Oklahoma Peptide compounds and methods of production and use thereof
US20200157159A1 (en) 2013-04-16 2020-05-21 The Board Of Regents Of The University Of Oklahoma Peptide compounds and compositions thereof
US10266579B2 (en) 2014-09-14 2019-04-23 Tel Hashomer Medical Research Infrastructure And Services Ltd. Synthetic somatostatin receptor ligands
JP6856532B2 (ja) 2015-01-20 2021-04-07 エックスオーシー ファーマシューティカルズ インコーポレイテッドＸｏｃ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ エルゴリン化合物およびその使用
BR112017015510A2 (pt) 2015-01-20 2018-01-30 Xoc Pharmaceuticals Inc composto de fórmula estrutural (i), método de tratamento e/ou prevenção, método de agonização do receptor d2 em um indivíduo, método de antagonização do receptor d3 em um indivíduo, método de agonização do receptor 5-ht1d em um indivíduo, método de agonização do receptor 5-ht1a em um indivíduo, método de agonização seletiva do receptor 5-ht1d em vez do receptor 5-ht1b em um indivíduo, método de agonização seletiva do re-ceptor 5-ht2c em vez do receptor 5-ht2a ou 5-ht2b em um indivíduo, método de agonização do receptor 5-ht2c em um indivíduo, método de fornecimento de atividade antagonista funcional no receptor 5-ht2b ou receptor 5-ht7, e, método de fornecimento de atividade antagonista funcional nos receptores adrenérgicos em um indivíduo
MX2019014272A (es) 2017-06-01 2020-12-11 Xoc Pharmaceuticals Inc Compuestos policiclicos y usos de los mismos.
WO2023225043A1 (en) * 2022-05-18 2023-11-23 Kuleon Llc Tricyclic and tetracyclic serotonin receptor modulators and methods of making and using the same

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2619488A (en) * 1952-11-25 Method of preparing d
US2589978A (en) * 1952-03-18 Lysergyl and isolysergyl glycines
DE140044C (no)
NL128196C (no) * 1961-05-29
AT258479B (de) * 1961-05-29 1967-11-27 Farmaceutici Italia Verfahren zur Herstellung von neuen Verbindungen aus der Klasse des D-6-Methyl- (und -1,6-Dimethyl)-8-amino-methyl-ergolins I
US3966941A (en) 1970-09-23 1976-06-29 Spofa United Pharmaceutical Works Composition for preventing lactation or pregnancy in mammals and the method for using the same
US3901894A (en) 1974-06-06 1975-08-26 Lilly Co Eli 8-thiomethylergolines
US4291022A (en) 1975-03-11 1981-09-22 Sandoz Ltd. Organic compounds
HU172479B (hu) 1976-03-09 1978-09-28 Gyogyszerkutato Intezet Sposob poluchenija novykh soedinenij s ehrgolenovymi i
US4133782A (en) 1976-06-07 1979-01-09 The Salk Institute For Biological Studies Somatostatin analogs with dissociated biological activities
US4190575A (en) 1977-12-27 1980-02-26 American Home Products Corporation Polypeptides related to somatostatin
EP0000053B1 (en) 1977-06-08 1981-05-27 Merck & Co. Inc. Somatostatin analogs, process for their preparation and pharmaceutical compositions containing them
US4357259A (en) 1977-08-01 1982-11-02 Northwestern University Method of incorporating water-soluble heat-sensitive therapeutic agents in albumin microspheres
US4211693A (en) 1977-09-20 1980-07-08 The Salk Institute For Biological Studies Peptides with para-substituted phenylalanine
LU78191A1 (de) 1977-09-28 1979-05-25 Ciba Geigy Ag Verfahren zur herstellung von neuen cyclopeptiden
US4166182A (en) * 1978-02-08 1979-08-28 Eli Lilly And Company 6-n-propyl-8-methoxymethyl or methylmercaptomethylergolines and related compounds
CA1107273A (en) 1978-05-19 1981-08-18 Chester A. Meyers Somatostatin analogs having a substituted tryptophyl residue in position eight
JPS5819669B2 (ja) 1978-10-28 1983-04-19 白井松新薬株式会社 新規生理活性ペプチド化合物及びその製造法
DD140044A1 (de) * 1978-11-08 1980-02-06 Guenter Losse Verfahren zur herstellung von lysergyl-enkephalin-derivaten
US4215039A (en) 1979-02-15 1980-07-29 American Home Products Corporation Somatostatin analogues
US4190648A (en) 1979-03-13 1980-02-26 Merck & Co., Inc. Peptides having somatostatin activity
US4316890A (en) 1979-03-16 1982-02-23 Ciba-Geigy Corporation Peptides and processes for the manufacture thereof
US4209426A (en) 1979-05-29 1980-06-24 American Home Products Corporation Polypeptides related to somatostatin
US4328214A (en) 1979-07-04 1982-05-04 Ciba-Geigy Corporation Cyclopeptides and pharmaceutical preparations thereof and also processes for their manufacture
US4235886A (en) 1979-10-31 1980-11-25 Merck & Co., Inc. Cyclic hexapeptide somatostatin analogs
US4310518A (en) 1979-10-31 1982-01-12 Merck & Co., Inc. Cyclic hexapeptide somatostatin analogs
ATE2512T1 (de) 1979-11-27 1983-03-15 Sandoz Ag Polypeptide, verfahren zu ihrer herstellung, pharmazeutische zusammensetzungen, die diese polypeptide enthalten, und ihre verwendung.
US4369179A (en) 1979-12-14 1983-01-18 Ciba-Geigy Corporation Acylpeptides
DD155985A5 (de) 1979-12-21 1982-07-21 Ciba Geigy Ag Verfahren zur herstellung cyclischr octapeptide
US4282143A (en) 1980-06-13 1981-08-04 American Home Products Corporation Octapeptides lowering growth hormone
US4526892A (en) * 1981-03-03 1985-07-02 Farmitalia Carlo Erba, S.P.A. Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas
DK81082A (da) 1981-03-06 1982-09-07 Sandoz Ag Fremgangsmaade til fremstilling af polypeptider
US4360516A (en) 1981-04-13 1982-11-23 Merck & Co., Inc. Modified D-retro cyclic hexapeptide somatostatin analogs
GB2103603B (en) 1981-08-11 1985-04-11 Erba Farmitalia Ergoline derivatives
GB2112382B (en) 1981-11-06 1985-03-06 Erba Farmitalia Ergoline derivatives
EP0083305B1 (de) 1981-12-24 1985-07-10 Ciba-Geigy Ag Cyclische Octapeptide und pharmazeutische Präparate davon, sowie Verfahren zur Herstellung derselben und ihre Anwendung
FR2522655B1 (fr) 1982-03-05 1987-03-06 Sanofi Sa Analogues de la somatostatine possedant une liaison du type hydrazide et medicaments en contenant
PH21123A (en) 1983-04-28 1987-07-27 Erba Farmitalia Ergoline derivatives
US4486415A (en) 1983-08-15 1984-12-04 Merck & Co., Inc. Cyclic hexapeptide somatostatin analogs
US4485101A (en) 1983-10-11 1984-11-27 Administrators Of The Tulane Educational Fund Peptides
US4522813A (en) 1983-10-27 1985-06-11 Merck & Co., Inc. Cyclic hexapeptide somatostatin analogs
US4684620A (en) 1984-09-04 1987-08-04 Gibson-Stephens Neuropharmaceuticals, Inc. Cyclic polypeptides having mu-receptor specificity
HUT42101A (en) 1985-01-07 1987-06-29 Sandoz Ag Process for preparing stomatostatine derivatives and pharmaceutical compositions containing such compounds
US4725577A (en) 1985-04-25 1988-02-16 Administrators Of The Tulane Educational Fund Biologically active lysine containing octapeptides
US4650787A (en) 1985-04-25 1987-03-17 Schally Andrew Victor Biologically active octapeptides
US4585755A (en) 1985-04-29 1986-04-29 Merck & Co., Inc. Cyclic and bridged cyclic somatostatin analogs useful as local anti-inflammatory agents
US4904642A (en) 1985-09-12 1990-02-27 The Administrators Of The Tulane Educational Fund Therapeutic somatostatin analogs
US4853371A (en) 1986-06-17 1989-08-01 The Administrators Of The Tulane Educational Fund Therapeutic somatostatin analogs
HU906340D0 (en) 1986-10-13 1991-04-29 Sandoz Ag Synthesis in solid phase for producing peptonic alcohols
US4871717A (en) 1987-01-07 1989-10-03 Administrators Of The Tulane Educational Fund Peptides
DE3845000C2 (de) 1987-07-10 1998-11-19 Novartis Ag Anwendung von Octreotid zur Behandlung von Brustkrebs
EP0397779A1 (en) 1988-02-01 1990-11-22 The Upjohn Company Renin inhibiting peptides with polar end groups
GB8813339D0 (en) 1988-06-06 1988-07-13 Sandoz Ltd Improvements in/relating to organic compounds
DK375789A (da) 1988-08-18 1990-02-19 Syntex Inc Peptidderivater
CA2012115C (en) 1989-03-15 2001-07-03 Biomeasure, Inc. Iodinated somatostatins
WO1990012811A1 (en) 1989-04-26 1990-11-01 The Administrators Of The Tulane Educational Fund Linear somatostatin analogs
US5621133A (en) * 1989-05-31 1997-04-15 Deninno; Michael P. Dopamine agonists
HU203549B (en) 1989-06-27 1991-08-28 Richter Gedeon Vegyeszet New stereoselektive hydrogenating process for producing dihydro-lisergol
DK0457888T3 (da) 1989-12-08 1996-08-12 Univ Tulane Octapeptidanaloger af somatostatin med threonin i 6-stillingen
US5411966A (en) 1990-01-15 1995-05-02 Schering Aktiengesellschaft 2, 13-disubstituted ergolines, their production and use in pharmaceutical agents
RU2074857C1 (ru) 1990-01-25 1997-03-10 Фармиталиа Карло Эрба С.Р.Л. Способ получения производных эрголина
US5043341A (en) 1990-04-11 1991-08-27 Eli Lilly And Company N-(2-hydroxycyclopentyl)-1-isopropyl-6-methylergoline-8-carboxamides
IT1240643B (it) 1990-05-11 1993-12-17 Mediolanum Farmaceutici Spa Peptidi biologicamente attivi contenenti in catena 2-alchiltriptofano
AU8427291A (en) * 1990-07-10 1992-02-04 Neurogenetic Corporation Nucleic acid sequences encoding a human dopamine d1 receptor
HU207104B (en) 1991-01-25 1993-03-01 Biosignal Kutato Fejlesztoe Kf Process for producing new somatostatin analogs inhibiting tumour growth and pharmaceutical compositions comprising such compounds
EP0658229A4 (en) 1992-08-20 1997-10-08 Ind Progress Inc PROCESS FOR PRODUCING PAPER UNDER ACIDAL ALKALINE CONDITIONS.
WO1994014806A1 (en) 1992-12-24 1994-07-07 Farmitalia Carlo Erba S.R.L. Serotoninergic ergoline derivatives
FR2699923B1 (fr) 1992-12-28 1995-03-17 Great Lakes Chemical France Copolymères d'esters gras insaturés, leur utilisation comme additif de viscosité et huile lubrifiante contenant lesdits copolymères.
BR9405664A (pt) 1993-01-21 1996-04-30 Univ Georgia Composto imunogenio processos para evitar a toxicose por festuca em um herbivoro para tratar a toxicose por festuca em um herbivoro anticorpo purificado lingagem de célula de hidridoma e anticorpo
MY147327A (en) 1995-06-29 2012-11-30 Novartis Ag Somatostatin peptides
US6025193A (en) * 1996-03-15 2000-02-15 Allegheny University Of The Health Sciences Methods and compositions for diagnosis and treatment of pathological conditions related to abnormal dopamine receptor expression
US5925618A (en) * 1997-03-06 1999-07-20 American Cyanamid Company Peptides useful as somatostatin antagonists
GB9711043D0 (en) * 1997-05-29 1997-07-23 Ciba Geigy Ag Organic compounds
DE19832191A1 (de) 1998-07-17 2000-01-27 Knoell Hans Forschung Ev Neuartige Ergolinamin-Derivate und ihre Verwendung

Also Published As

Publication number Publication date
EP2062914A3 (en) 2009-08-05
ES2325880T3 (es) 2009-09-23
CA2449634C (en) 2011-08-02
PL216217B1 (pl) 2014-03-31
EP1401863A4 (en) 2006-04-26
KR100620435B1 (ko) 2006-09-12
HUP0400245A3 (en) 2012-09-28
KR100754917B1 (ko) 2007-09-04
US7579435B2 (en) 2009-08-25
US20100179304A1 (en) 2010-07-15
US7572883B2 (en) 2009-08-11
IL201310A (en) 2012-06-28
TWI318214B (en) 2009-12-11
JP3996897B2 (ja) 2007-10-24
CN101481405A (zh) 2009-07-15
KR20040004699A (ko) 2004-01-13
ATE424414T1 (de) 2009-03-15
DK2062914T3 (da) 2014-07-14
HUP0400245A2 (hu) 2004-08-30
RU2277539C2 (ru) 2006-06-10
BR0210915A (pt) 2004-06-08
CN1514843A (zh) 2004-07-21
NO332042B1 (no) 2012-06-11
PT2062914E (pt) 2014-07-18
KR20050118740A (ko) 2005-12-19
JP4181203B2 (ja) 2008-11-12
DK1401863T3 (da) 2009-05-25
RU2004100109A (ru) 2005-06-27
DE60231403D1 (de) 2009-04-16
CZ305160B6 (cs) 2015-05-27
HK1060360A1 (en) 2004-08-06
IL158922A0 (en) 2004-05-12
NO338459B1 (no) 2016-08-15
ES2483722T3 (es) 2014-08-07
WO2002100888A1 (en) 2002-12-19
US20090275501A1 (en) 2009-11-05
JP2005503357A (ja) 2005-02-03
NO20111165L (no) 2004-01-28
CA2449634A1 (en) 2002-12-19
EP1401863A1 (en) 2004-03-31
EP1401863B1 (en) 2009-03-04
US20060211607A1 (en) 2006-09-21
US8324386B2 (en) 2012-12-04
PL364457A1 (en) 2004-12-13
US20040209798A1 (en) 2004-10-21
PT1401863E (pt) 2009-07-23
KR20060090842A (ko) 2006-08-16
AU2002305845B2 (en) 2006-03-30
EP2062914A2 (en) 2009-05-27
KR100743212B1 (ko) 2007-07-26
AR037226A1 (es) 2004-11-03
NZ530007A (en) 2006-02-24
JP2007224033A (ja) 2007-09-06
CZ20033122A3 (cs) 2004-05-12
EP2062914B1 (en) 2014-05-07
US8178651B2 (en) 2012-05-15
MXPA03011321A (es) 2004-12-06

Similar Documents

Publication Publication Date Title
DK2062914T3 (da) Somatostatin-dopamin-chimære analoger
NO20054371D0 (no) Somatostatin-dopamin kimaere analoger
ATE402148T1 (de) Substituierte pyridinylamine
DE50206892D1 (de) Substituierte imidazotriazinone
DK1373228T3 (da) Substituerede fluoralkoxyphenylsulfonylurinstoffer
DE50213651D1 (de) Substituierte 4-aminocyclohexanole
NO20041066L (no) Hydroksyeikosensyre-analoger
DE60216967D1 (de) Substituierte cyclohexanderivate
SE0103820D0 (sv) Novel compounds
SE0100966D0 (sv) Novel compounds
SE0102618D0 (sv) Novel compounds
SE0104141D0 (sv) Novel compounds
SE0104472D0 (sv) Novel Compounds
SE0104473D0 (sv) Novel Compounds
SE0104474D0 (sv) Novel Compounds
SE0200704D0 (sv) Novel compounds
SE0102403D0 (sv) Novel compounds
SE0102807D0 (sv) Novel compounds
SE0102156D0 (sv) Novel compounds
SE0102094D0 (sv) Novel compounds
SE0102053D0 (sv) Novel compounds
SE0101933D0 (sv) Novel compounds
SE0101617D0 (sv) Novel compounds
SE0101321D0 (sv) Novel compounds
SE0103271D0 (sv) Novel compounds

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees